from the speedily evolving area of cancer therapeutics, being familiar with the intricate mechanisms of Antibody-Drug Conjugates (ADCs) is crucial for producing productive solutions. The most promising strategies is using in vitro bystander outcome assays, which Participate in a pivotal function in improving therapeutic efficacy. These assays, prov